Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC5131 dose response in hospitalized COVID-19 patients
NCT04555148Phase 2Completed
- Sponsor
- GC Biopharma
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- IgG Antibodies, Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gc5131 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by GC Biopharma. Primary endpoint: Ordinal scale outcome at 28 days. Started Sep 2020; status: completed.
02
Drugs
gc5131
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04555148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555148.